Efficacy and safety of One-day transdermal fentanyl switching from immediately-release oxycodone in advanced breast cancer patients. - Efficacy and safety of One-day transdermal fentanyl switching from immediately-release oxycodone in advanced breast cancer patients.

Saitama Breast Cancer Clinical Study Group0 个研究点目标入组 90 人开始时间: 2012年4月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Oxnorm Contraindications 1)Severe respiratory depression, severe COPD 2)During acute attack of bronchial asthma 3)Secondary cardiac failure of chronic pulmonary diseases 4)During convulsive state 5)Paralytic ileus 6)Hypersensitivity to a group of opium alkaloids 7)Hemorrhagic colitis 8)Bacterial diarrhea OneDuro Patch Contraindication 1)hypersensitivity to any of the ingredients of the product Careful Administration 2)Respiratory dysfunctions such as chronic lung diseases 3)Asthma 4)Severe bradyarrhythmia 5)Severe hepatic or renal dysfunction 6)Organic brain disorders such as intracranial hypertension, disturbed consciousness, coma or brain cancer 7)Skin diseases such as atopic dermatitis ieczema on adhesive site 8)40dgree or more fever 9)History of drug dependence 10)Pregnancy, nursing women 11)Within next 2 days before using Fentanyl patch, antagonists of opioid receptor such as Pentazocine or Buprenorphine etc. are administered or planned to administer 12)below the age of 20 13)Attending doctors judgement

发起方

Saitama Breast Cancer Clinical Study Group